Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's Sinovac Just Steps Away From Crossing Global Finish Line In Race To Launch A/H1N1 Vaccine

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Just days away from widely expected regulatory approval for an A/H1N1 vaccine, the Beijing-based Sinovac Biotech is now virtually guaranteed to become the first producer in the world to market a defense to the swine flu pandemic

You may also be interested in...



Chinese Regulators Report Steady Progress In Promoting Innovation - DIA China Conference

BEIJING - China's State FDA has made steady progress in meeting the challenges of drug supervision while at the same time encouraging innovation and ensuring safety, SFDA Deputy Commissioner Wu Zhen told executives and scientists during the second Drug Information Association China annual meeting in Beijing this week

Chinese Regulators Report Steady Progress In Promoting Innovation - DIA China Conference

BEIJING - China's State FDA has made steady progress in meeting the challenges of drug supervision while at the same time encouraging innovation and ensuring safety, SFDA Deputy Commissioner Wu Zhen told executives and scientists during the second Drug Information Association China annual meeting in Beijing this week

Korea FDA Evaluating H1N1 Vaccine Applications from GSK and Three Korean Pharmas

SEOUL - Korea FDA said it is evaluating three applications for the A/H1N1 flu vaccine submitted by GlaxoSmithKline and Korean companies Green Cross, Boryung Pharmaceutical and Hanwha Pharma

Related Content

UsernamePublicRestriction

Register

LL1132999

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel